검색어: haemangioma (영어 - 에스토니아어)

haemangioma can be superficial or deep.
hemangioom võib olla pinnapealne või sügav.

life- or function-threatening haemangioma,
hemangioom, mis on eluohtlik või häirib organismi funktsioneerimist;

this medicine is used to treat a disease called haemangioma.
seda ravimit kasutatakse hemangioomi ravimiseks.

the committee concluded that hemangiol was an effective treatment for haemangioma.
komitee jõudis järeldusele, et hemangiol oli hemangioomi ravimisel efektiivne.

hemangiol is indicated in the treatment of proliferating infantile haemangioma requiring systemic therapy:
hemangiol on näidustatud süsteemset ravi vajava prolifereeruva infantiilse hemangioomi raviks:

a haemangioma is a collection of extra blood vessels that have formed a lump in or under the skin.
hemangioom on täiendavate veresoonte kogum, mis on nahka või naha alla moodustanud muhu.

treatment should be started by a doctor who has experience in the diagnosis, treatment and management of infantile haemangioma.
ravi tohib alustada üksnes infantiilse hemangioomi diagnoosimises, ravis ja ravikorralduses kogenud arst.

in rats, the incidence of benign haemangioma of the mesenteric lymph nodes was higher in some groups than in concurrent controls.
rottidel oli mesenteriaalsete lümfisõlmede healoomulise hemangioomi esinemissagedus mõnedes gruppides suurem kui kontroll-loomadel.

it is sometimes called ‘strawberry mark’ because the surface of a haemangioma looks a bit like a strawberry.
seda kutsutakse vahel „maasikajäljeks”, sest hemangioomi pind meenutab maasikat.

for ethical reasons related to the use of placebo, the demonstration of the efficacy was not established in patients with high-risk haemangioma.
platseebo kasutamisega seotud eetilistel kaalutlustel ei demonstreeritud efektiivsust kõrge riskiastmega hemangioomiga patsientidel.

evidence of the efficacy of propranolol in patients with high- risk haemangioma is available both in literature and in a specific compassionate use program performed with hemangiol.
propranolooli efektiivsuse kohta kõrge riskiastmega hemangioomiga patsientidel on saadaval ulatuslikult tõendusmaterjale nii kirjandusest kui ka hemangioliga läbi viidud spetsiaalsest ravimi tasuta kasutamise programmist.

patients with infantile haemangioma may be at increased risk if they have received or are concomitantly receiving treatment with corticosteroids because adrenal suppression may result in loss of the counterregulatory cortisol response and increase the risk of hypoglycaemia.
infantiilse hemangioomiga patsiendid võivad olla ohustatud, kui nad on võtnud või saavad samaaegselt ravi kortikosteroididega, sest neerupealiste allasurumine võib vähendada kortisooli glükoositaset reguleerivat vastust ja suurendada hüpoglükeemia ohtu.

the educational pack must be available for distribution prior to the launch of the new indication (treatment of proliferating infantile haemangioma) in the member state.
Õppepakk peab olema levitamiseks saadaval enne uue kasutusnäidustuse (prolifereeruva infantiilse hemangioomi ravi) liikmesriigis turule laskmist.

treatment success was defined as a complete or nearly complete resolution of the target haemangioma, which was evaluated by blinded centralized independent assessments made on photographs at week 24, in the absence of premature treatment discontinuation.
ravi õnnestumiseks oli määratletud sihthemangioomi täielik või peaaegu täielik lahenemine, mida hinnati 24. nädalal fotodel pimemenetlusega, tsentraliseeritult ja sõltumatult, kui ravi enneaegselt ei lõpetatud.

it is used to treat children with proliferating infantile haemangioma, which are benign tumours (abnormal non-cancerous growths) of blood vessels.
seda kasutatakse selliste laste ravimiseks, kellel on prolifereeruv infantiilne hemangioom ehk veresoonte healoomuline kasvaja.

in clinical trials for proliferating infantile haemangioma, the most frequently reported adverse reactions in infant treated with hemangiol were sleep disorders, aggravated respiratory tract infections such as bronchitis and bronchiolitis associated with cough and fever, diarrhoea, and vomiting.
prolifereeruva infantiilse hemangioomi kliinilistes uuringutes esines hemangioliga ravitud imikutel kõrvaltoimetena kõige sagedamini unehäireid, raskeid hingamisteede infektsioone, nagu bronhiit ja bronhioliit, millega kaasnesid köha, palavik, kõhulahtisus ja oksendamine.

although it is not exactly known how hemangiol works in proliferative infantile haemangioma, it is thought to do so by several mechanisms including narrowing the blood vessels and so decreasing blood supply to the haemangioma, blocking the formation of new blood vessels in the growth, triggering cell death of the abnormal blood vessel cells and blocking the effect of certain proteins (called vegf and bfgf), which are important for the growth of blood vessels.
kuigi hemangioli toime prolifereeruva infantiilse hemangioomi korral ei ole täpselt teada, arvatakse, et see toimib eri mehhanismide kaudu, sealhulgas veresoonte ahendamine ja seeläbi hemangioomi verevarustuse vähendamine, kasvajas uute veresoonte tekkimise blokeerimine, ebanormaalsete veresoonte rakkude hävitamine ja veresoonte kasvamiseks vajalike teatud valkude (vegf ja bfgf) toime blokeerimine.